Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.084
Neutral
RSI(14)
38.264
Neutral
STOCH(KDJ)(9,3,3)
41.082
Neutral
ATR(14)
0.419
Low Volatility
CCI(14)
-37.307
Neutral
Williams %R
75.817
Sell
TRIX(12,20)
-1.014
Sell
StochRSI(14)
50.357
Sell
Search
LENZ Therapeutics Inc
LENZAdd to Watchlist
5.124USD
+0.074+1.47%
Market hours （ET）Quotes delayed by 15 min
160.61MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.47%
5 Days
+5.00%
1 Month
-10.89%
6 Months
-74.93%
Year to Date
-67.97%
1 Year
-84.50%
Key Figures
5.060Open
5.210High
151.22KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.48%Turnover Ratio
5.050Prev. Close
5.030Low
584.40KTurnover
LossP/E Static
0.56P/B
0.00%Div Yield TTM
-46.01%ROA
50.40052wk High
1.28Volume Ratio
-49.77MNet Profit
31.34MShares
-3.6425EPS TTM
0.66Beta
-49.71%ROE
6.61052wk Low
3.56%Amplitude
43.40%Gross Margin
160.61MMarket Cap
-2.00Reward/Risk
4.76%Risk Rate
TradingKey Stock Score of LENZ Therapeutics Inc
Currency: USD Updated: 2026-07-23Key Insights
LENZ Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 107 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.17.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LENZ Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
LENZ Therapeutics Inc Highlights
StrengthsRisks
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Growing
The company is in a growing phase, with the latest annual income totaling USD 19.09M.
Fairly Valued
The company’s latest PE is -1.39, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 36.30M shares, increasing 2.30% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 16.46K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.86.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
30.167
Target Price
+484.63%
Upside Space
LENZ Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
7
analysts
Buy
Current Rating
30.167
Target Price
+484.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
54
Total
5
Median
7
Average
Company name
Ratings
Analysts
LENZ Therapeutics Inc
LENZ
7
Apple Inc
AAPL
48
Ge Vernova Inc
GEV
38
Tapestry Inc
TPR
24
Verisk Analytics Inc
VRSK
20
Avantor Inc
AVTR
19
1
2
3
...
11
Indicators
Moving Average
Indicators
Value
Direction
MA5
5.138
Sell
MA10
5.131
Sell
MA20
5.459
Sell
MA50
6.376
Sell
MA100
8.317
Sell
MA200
15.812
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
LENZ Therapeutics Inc Info
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Ticker SymbolLENZ
CompanyLENZ Therapeutics Inc
CEOSchimmelpennink (Evert)
Website
Shareholders
Related Instruments
+1.06%
+1.20%
+0.84%
+1.17%
+0.36%
-0.23%
+1.38%
+2.24%
-0.25%
+0.31%
+1.07%
+1.42%
+1.28%
-0.18%
+0.74%
0.00%
+1.42%
-0.18%
+2.94%
+0.69%Popular Instruments
51883.900
+159.900 (+0.31%)
28264.600
-313.400 (-1.10%)
7417.900
-2.000 (-0.03%)
14984.000
-117.000 (-0.78%)
64687.000
-684.000 (-1.05%)
6253.300
+37.600 (+0.60%)
89.353
-2.759 (-3.00%)
327.640
+5.980 (+1.86%)
205.850
-2.910 (-1.39%)
4061.520
+12.150 (+0.30%)
FAQs
What is the current price of LENZ Therapeutics Inc (LENZ)?
The current price of LENZ Therapeutics Inc (LENZ) is 5.03.
What is the symbol of LENZ Therapeutics Inc?
The ticker symbol of LENZ Therapeutics Inc is LENZ.
What is the 52-week high of LENZ Therapeutics Inc?
The 52-week high of LENZ Therapeutics Inc is 50.40.
What is the 52-week low of LENZ Therapeutics Inc?
The 52-week low of LENZ Therapeutics Inc is 6.61.
What is the market capitalization of LENZ Therapeutics Inc?
The market capitalization of LENZ Therapeutics Inc is 157.66M.
Is LENZ Therapeutics Inc (LENZ) currently rated as Buy, Hold, or Sell?
According to analysts, LENZ Therapeutics Inc (LENZ) has an overall rating of Buy, with a price target of 30.17.
What is the Earnings Per Share (EPS TTM) of LENZ Therapeutics Inc (LENZ)?
The Earnings Per Share (EPS TTM) of LENZ Therapeutics Inc (LENZ) is -2.85.